-
Allero Therapeutics‘ Immunotherapy Approach in Food-Induced Immune Disorders Validated by Two Peer-Reviewed Publications
Allero Therapeutics BV, a Dutch oromucosal immunotherapy company, today announced the publication of two studies further detailing and validating its approach to combat food-induced immune disorders with its SOMIT (Specific OroMucosal ImmunoTherapy) platform technology. The first study, published with collaborators from Madrid in Frontiers in Immunology, validates Allero’s SOMIT approach of addressing the oral mucosa as an immune privilege and an important target for the treatment of patients with Celiac disease (CD). Celiac disease is a chronic autoimmune disease characterized by an immune-triggered enteropathy upon gluten intake. The study compared mRNA patterns and immunohistological parameters of the oral mucosa of patients with CD (both chronic and newly diagnosed) and healthy…
-
Allero Therapeutics and Abbreos join forces to clinically develop COVID-19 program
Allero Therapeutics BV, a Belgian-Dutch oromucosal immunotherapy company, and Abbreos Inc., a US- based IND-stage company focused on developing treatments that dampen hyperactive immune responses, today announced a clinical development agreement to treat medical conditions associated with potentially lethal amounts of pro-inflammatory cytokines and chemokines (“cytokine storm”). A first focus of the agreement is the treatment of patients likely to progress into COVID-19-associated acute respiratory distress syndrome (ARDS). The goal of the collaboration is to clinically test the novel OroMucosal ImmunoGlobulin (OMIG) concept developed by Allero in a first set of COVID-19 infected patients that may advance to ARDS and, if not treated, require extensive ICU support and ventilation. Clinical…
